Hong Kong Stock Market Update | Maike Medical-B (02335.HK) rises over 3% as the Phase II clinical trial of MT200605 for treating acute ischemic stroke meets its primary endpoint.

Zhitong Finance APP learned that Maike Pharmaceutical-B (02335.HK) rose over 3%. As of the time of writing, it was up 3.4%, at HKD 30.4, with a trading volume of HKD 20.4952 million.